Suppression of BCL-2 synergizes cisplatin sensitivity in nasopharyngeal carcinoma cells

Cancer Letters

Volumn 314, Issue 2, 2012, Pages 166-175

  Low, Soon Yang ^a   Tan, Boon Shing ^a   Choo, Heng Lungh ^a   Tiong, Kai Hung ^a   Khoo, Alan Soo Beng ^b   Leong, Chee Onn ^a  

^a INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

^b INSTITUTE FOR MEDICAL RESEARCH   (Malaysia)

Author keywords

BCL 2; Cisplatin; Combination therapy; Nasopharyngeal carcinoma; Synergism; YC137

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 8; CISPLATIN; PACLITAXEL; PROTEIN BCL 2; PROTEIN INHIBITOR; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; YC 137; ANTINEOPLASTIC AGENT; THIAZOLE DERIVATIVE; YC137;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; NASOPHARYNX TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG SYNERGISM; HUMANS; NASOPHARYNGEAL NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; THIAZOLES;

EID: 84855730245     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.09.025     Document Type: Article

References (60)

1. K.W. Lo, K.F. To, D.P. Huang, Focus on nasopharyngeal carcinoma, Cancer Cell 5 (2004) 423-428.
2. W.I. Wei, J.S. Sham, Nasopharyngeal carcinoma, Lancet 365 (2005) 2041-2054.
3. E. Au, P.T. Ang, A phase II trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma, Ann. Oncol. 5 (1994) 87-89.
4. T.L. Wang, Y.O. Tan, Cisplatin and 5-fluorouracil continuous infusion for metastatic nasopharyngeal carcinoma, Ann. Acad. Med. Singapore 20 (1991) 601-603.
5. I. Ayan, E. Kaytan, N. Ayan, Childhood nasopharyngeal carcinoma: from biology to treatment, Lancet Oncol. 4 (2003) 13-21.
6. A.T. Chan, P.M. Teo, P.J. Johnson, Nasopharyngeal carcinoma, Ann. Oncol. 13 (2002) 1007-1015.
7. R.L. Hong, T.S. Sheen, J.Y. Ko, M.M. Hsu, C.C. Wang, L.L. Ting, Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study, Br. J. Cancer 80 (1999) 1962-1967.
8. B.B. Ma, A.T. Chan, Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma, Cancer 103 (2005) 22-31.
9. D.R. Green, G.I. Evan, A matter of life and death, Cancer Cell 1 (2002) 19-30.
10. J.C. Reed, Apoptosis-targeted therapies for cancer, Cancer Cell 3 (2003) 17-22.
11. S.Q. Fan, J. Ma, J. Zhou, W. Xiong, B.Y. Xiao, W.L. Zhang, C. Tan, X.L. Li, S.R. Shen, M. Zhou, Q.H. Zhang, Y.J. Ou, H.D. Zhuo, S. Fan, Y.H. Zhou, G.Y. Li, Differential expression of Epstein-Barr virus-encoded RNA and several tumor-related genes in various types of nasopharyngeal epithelial lesions and nasopharyngeal carcinoma using tissue microarray analysis, Human Pathol. 37 (2006) 593-605.
12. Q.L. Lu, G. Elia, S. Lucas, J.A. Thomas, Bcl-2 proto-oncogene expression in Epstein-Barr-virus-associated nasopharyngeal carcinoma, Int. J. Cancer 53 (1993) 29-35.
13. N. Raab-Traub, Epstein-Barr virus in the pathogenesis of NPC, Semin. Cancer Biol. 12 (2002) 431-441.
14. S. Henderson, M. Rowe, C. Gregory, D. Croom-Carter, F. Wang, R. Longnecker, E. Kieff, A. Rickinson, Induction of Bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death, Cell 65 (1991) 1107-1115.
15. W. Sheng, G. Decaussin, S. Sumner, T. Ooka, N-terminal domain of BARF1 gene encoded by Epstein-Barr virus is essential for malignant transformation of rodent fibroblasts and activation of BCL-2, Oncogene 20 (2001) 1176-1185.
16. W.A. Michaud, A.C. Nichols, E.A. Mroz, W.C. Faquin, J.R. Clark, S. Begum, W.H. Westra, H. Wada, P.M. Busse, L.W. Ellisen, J.W. Rocco, Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma, Clin. Cancer Res. 15 (2009) 1645-1654.
17. J.M. Adams, S. Cory, The Bcl-2 apoptotic switch in cancer development and therapy, Oncogene 26 (2007) 1324-1337.
18. C.O. Leong, N. Vidnovic, M.P. DeYoung, D. Sgroi, L.W. Ellisen, The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers, J. Clin. Invest. 117 (2007) 1370-1380.
19. L.Y. Lim, N. Vidnovic, L.W. Ellisen, C.O. Leong, Mutant p53 mediates survival of breast cancer cells, Br. J. Cancer 101 (2009) 1606-1612.
20. J.W. Rocco, C.O. Leong, N. Kuperwasser, M.P. DeYoung, L.W. Ellisen, P63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis, Cancer Cell 9 (2006) 45-56.
21. T.D. Bradshaw, E.L. Stone, V. Trapani, C.O. Leong, C.S. Matthews, R. te Poele, M.F. Stevens, Mechanisms of acquired resistance to 2-(4-Amino-3-methylphenyl)benzothiazole in breast cancer cell lines, Breast Cancer Res. Treat. 110 (2008) 57-68.
22. C.O. Leong, M. Gaskell, E.A. Martin, R.T. Heydon, P.B. Farmer, M.C. Bibby, P.A. Cooper, J.A. Double, T.D. Bradshaw, M.F. Stevens, Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo, Br. J. Cancer 88 (2003) 470-477.
23. C.O. Leong, M. Suggitt, D.J. Swaine, M.C. Bibby, M.F. Stevens, T.D. Bradshaw, In vitro, in vivo, and in silico analyses of the antitumor activity of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazoles, Mol. Cancer Ther. 3 (2004) 1565-1575.
24. V. Trapani, V. Patel, C.O. Leong, H.P. Ciolino, G.C. Yeh, C. Hose, J.B. Trepel, M.F. Stevens, E.A. Sausville, A.I. Loaiza-Perez, DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells, Br. J. Cancer 88 (2003) 599-605.
25. T.C. Chou, P. Talalay, Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors, Adv. Enzyme Regul. 22 (1984) 27-55.
26. S.W. Wong, K.H. Tiong, W.Y. Kong, Y.C. Yue, C.H. Chua, J.Y. Lim, C.Y. Lee, S.I. Quah, C. Fow, C. Chung, I. So, B.S. Tan, H.L. Choo, R. Rosli, S.K. Cheong, C.O. Leong, Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73, Breast Cancer Res. Treat. (2010).
27. S.W. Tsao, X. Wang, Y. Liu, Y.C. Cheung, H. Feng, Z. Zheng, N. Wong, P.W. Yuen, A.K. Lo, Y.C. Wong, D.P. Huang, Establishment of two immortalized nasopharyngeal epithelial cell lines using SV40 large T and HPV16E6/E7 viral oncogenes, Biochim. Biophys. Acta 1590 (2002) 150-158.
28. D. Zhai, C. Jin, A.C. Satterthwait, J.C. Reed, Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins, Cell Death Differ. 13 (2006) 1419-1421.
29. P.J. Real, Y. Cao, R. Wang, Z. Nikolovska-Coleska, J. Sanz-Ortiz, S. Wang, J.L. Fernandez-Luna, Breast cancer cells can evade apoptosismediated selective killing by a novel small molecule inhibitor of Bcl-2, Cancer Res. 64 (2004) 7947-7953.
30. E.D. Arisan, O. Kutuk, T. Tezil, C. Bodur, D. Telci, H. Basaga, Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells, Breast Cancer Res. Treat. (2009).
31. H.J. Cho, J.K. Kim, K.D. Kim, H.K. Yoon, M.Y. Cho, Y.P. Park, J.H. Jeon, E.S. Lee, S.S. Byun, H.M. Lim, E.Y. Song, J.S. Lim, D.Y. Yoon, H.G. Lee, Y.K. Choe, Upregulation of Bcl-2 is associated with cisplatinresistance via inhibition of Bax translocation in human bladder cancer cells, Cancer Lett. 237 (2006) 56-66.
32. J.Y. Han, E.K. Hong, B.G. Choi, J.N. Park, K.W. Kim, J.H. Kang, J.Y. Jin, S.Y. Park, Y.S. Hong, K.S. Lee, Death receptor 5 and Bcl-2 protein expression as predictors of tumor response to gemcitabine and cisplatin in patients with advanced non-small-cell lung cancer, Med. Oncol. 20 (2003) 355-362.
33. S.H. Jeong, J.H. Jung, J.H. Han, J.H. Kim, Y.W. Choi, H.W. Lee, S.Y. Kang, Y.H. Hwang, M.S. Ahn, J.H. Choi, Y.T. Oh, M. Chun, S. Kang, K.J. Park, S.C. Hwang, S.S. Sheen, Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy, Lung Cancer 68 (2010) 288-294.
34. H. Miyake, N. Hanada, H. Nakamura, S. Kagawa, T. Fujiwara, I. Hara, H. Eto, K. Gohji, S. Arakawa, S. Kamidono, H. Saya, Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer, Oncogene 16 (1998) 933-943.
35. J. Wang, J.Y. Zhou, L. Zhang, G.S. Wu, Involvement of MKP-1 and Bcl-2 in acquired cisplatin resistance in ovarian cancer cells, Cell Cycle 8 (2009) 3191-3198.
36. Y. Gazitt, M.L. Rothenberg, S.G. Hilsenbeck, V. Fey, C. Thomas, W. Montegomrey, Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells, Int. J. Oncol. 13 (1998) 839-848.
37. E. Chun, K.Y. Lee, Bcl-2 and Bcl-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells, Biochem. Biophys. Res. Commun. 315 (2004) 771-779.
38. A. Cossarizza, M. Baccarani-Contri, G. Kalashnikova, C. Franceschi, A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,50,6,60-tetrachloro-1,10,3,30-tetraethylbenzimidazolcarbocyanine iodide (JC-1), Biochem. Biophys. Res. Commun. 197 (1993) 40-45.
39. A.W. Lee, W.M. Sze, T.K. Yau, R.M. Yeung, R. Chappell, J.F. Fowler, Retrospective analysis on treating nasopharyngeal carcinoma with accelerated fractionation (6 fractions per week) in comparison with conventional fractionation (5 fractions per week): report on 3-year tumor control and normal tissue toxicity, Radiother. Oncol. 58 (2001) 121-130.
40. K. Sultanem, H.K. Shu, P. Xia, C. Akazawa, J.M. Quivey, L.J. Verhey, K.K. Fu, Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: the University of California-San Francisco experience, Int. J. Radiat. Oncol. Biol. Phys. 48 (2000) 711-722.
41. N. Lee, P. Xia, J.M. Quivey, K. Sultanem, I. Poon, C. Akazawa, P. Akazawa, V. Weinberg, K.K. Fu, Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience, Int. J. Radiat. Oncol. Biol. Phys. 53 (2002) 12-22.
42. K.W. Yip, J.D. Mocanu, P.Y. Au, G.T. Sleep, D. Huang, P. Busson, W.C. Yeh, R. Gilbert, B. O'Sullivan, P. Gullane, C. Bastianutto, F.F. Liu, Combination Bcl-2 antisense and radiation therapy for nasopharyngeal cancer, Clin. Cancer Res. 11 (2005) 8131-8144.
43. F. Caponigro, F. Longo, F. Ionna, F. Perri, Treatment approaches to nasopharyngeal carcinoma: a review, Anticancer Drugs 21 (2010) 471-477.
44. B.A. Chabner, T.G. Roberts, Jr., Timeline: chemotherapy and the war on cancer, Nat. Rev. Cancer 5 (2005) 65-72.
45. Y. Sedletska, M.J. Giraud-Panis, J.M. Malinge, Cisplatin is a DNAdamaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways, Curr. Med. Chem. Anticancer Agents 5 (2005) 251- 265.
46. Z.H. Siddik, Cisplatin: mode of cytotoxic action and molecular basis of resistance, Oncogene 22 (2003) 7265-7279.
47. J.E. Chipuk, T. Moldoveanu, F. Llambi, M.J. Parsons, D.R. Green, The BCL-2 family reunion, Mol. Cell 37 (2010) 299-310.
48. A.S. Azmi, R.M. Mohammad, Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy, J. Cell. Physiol. 218 (2009) 13-21.
49. S.W. Tsao, G. Tramoutanis, C.W. Dawson, A.K. Lo, D.P. Huang, The significance of LMP1 expression in nasopharyngeal carcinoma, Semin. Cancer Biol. 12 (2002) 473-487.
50. L.S. Young, A.B. Rickinson, Epstein-Barr virus: 40 years on, Nat. Rev. Cancer 4 (2004) 757-768.
51. M.K. Chen, J.C. Lai, C.C. Chang, J.H. Chang, Y.J. Chang, H.C. Chen, Prognostic impact of Bcl-2 expression on advanced nasopharyngeal carcinoma, Head Neck 30 (2008) 1052-1057.
52. A. Fendri, C.K. Kontos, A. Khabir, R. Mokdad-Gargouri, A. Ardavanis, A. Scorilas, Quantitative analysis of BCL2 mRNA expression in nasopharyngeal carcinoma: an unfavorable and independent prognostic factor, Tumour Biol. 31 (2010) 391-399.
53. M.K. Chen, S.F. Yang, J.C. Lai, K.T. Yeh, J.S. Yang, L.S. Chen, H.C. Chen, Expression of Bcl-2 correlates with poor prognosis and modulates migration of nasopharyngeal carcinoma cells, Clin. Chim. Acta 411 (2010) 400-405.
54. U. Zangemeister-Wittke, T. Schenker, G.H. Luedke, R.A. Stahel, Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines, Br. J. Cancer 78 (1998) 1035-1042.
55. A. Schaaf, S. Sagi, S. Langbein, L. Trojan, P. Alken, M.S. Michel, Cytotoxicity of cisplatin in bladder cancer is significantly enhanced by application of Bcl-2 antisense oligonucleotides, Urol. Oncol. 22 (2004) 188-192.
56. S. Hopkins-Donaldson, R. Cathomas, A.P. Simoes-Wust, S. Kurtz, L. Belyanskaya, R.A. Stahel, U. Zangemeister-Wittke, Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment, Int. J. Cancer 106 (2003) 160- 166.
57. V. Wacheck, D. Losert, P. Gunsberg, H.P. Vornlocher, P. Hadwiger, A. Geick, H. Pehamberger, M. Muller, B. Jansen, Small interfering RNA targeting Bcl-2 sensitizes malignant melanoma, Oligonucleotides 13 (2003) 393-400.
58. G. Zupi, M. Scarsella, S.C. Semple, M. Mottolese, P.G. Natali, C. Leonetti, Antitumor efficacy of Bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence, Clin. Cancer Res. 11 (2005) 1990-1998.
59. R. Kim, M. Emi, K. Tanabe, T. Toge, Preclinical evaluation of antisense Bcl-2 as a chemosensitizer for patients with gastric carcinoma, Cancer 101 (2004) 2177-2186.
60. V. Wacheck, E. Heere-Ress, J. Halaschek-Wiener, T. Lucas, H. Meyer, H.G. Eichler, B. Jansen, Bcl-2 antisense oligonucleotides chemosensitize human gastric cancer in a SCID mouse xenotransplantation model, J. Mol. Med. 79 (2001) 587-593.